End Cash (Quarterly)

End Cash: The amount of cash held by the company for the given period.

Aquestive Therapeutics, Inc. (AQST) had End Cash of $129.06M for the most recently reported fiscal quarter, ending 2025-09-30.

Quarterly Annual

Figures for fiscal quarter ending 2025-09-30

Income Statement Financials
Revenue	$12.81M
Net Income	$-15.45M
Cost of Goods Sold	$4.51M
Gross Profit	$8.30M
Operating Expenses	$24.29M
Operating Income	$-11.48M
Non-Operating Income/Expense	$-3.97M
Pre-Tax Income	$-15.45M
Normalized Pre-Tax Income	$-15.45M
Income after Taxes	$-15.45M
Income from Continuous Operations	$-15.45M
Consolidated Net Income/Loss	$-15.45M
Normalized Income after Taxes	$-15.45M
EBIT	$-11.48M
EBITDA	$-8.59M
Weighted-Average Shares Outstanding (Basic)	110.58M
Weighted-Average Shares Outstanding (Diluted)	110.58M
Earnings per Share (EPS) (Basic)	$-0.14
Earnings per Share (EPS) (Diluted)	$-0.14
Balance Sheet Financials
Current Assets	$151.67M
Property, Plant, and Equipment	$3.92M
Long-Term Assets	$11.89M
Total Assets	$163.56M
Current Liabilities	$25.57M
Long-Term Debt	$29.94M
Long-Term Liabilities	$142.09M
Total Liabilities	$167.67M
Common Equity	$-4.11M
Tangible Shareholders Equity	$-4.11M
Shareholders Equity	$-4.11M
Common Shares Outstanding	121.66M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-43.96M
Cash Flow from Investing Activities	$-0.48M
Cash Flow from Financial Activities	$101.96M
Beginning Cash	$71.55M
End Cash	$129.06M
Increase/Decrease in Cash	$57.52M
Stock-Based Compensation	$6.25M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	5.93
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	1.16
Debt to Equity Ratio	-7.29
Gross Margin	64.82%
Operating Margin	-89.63%
EBIT Margin	-89.63%
EBITDA Margin	--
Pre-Tax Profit Margin	-120.61%
Profit Margin	-120.61%
Free Cash Flow	$-44.44M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.08
Inventory Turnover	0.57
Receiveable Turnover	1.09
Days Sales in Receivables	82.93
Return on Equity	375.91%
Return on Tangible Equity	375.91%
Return on Assets	-9.44%
Return on Investments	-59.80%
Book Value Per Share	$-0.03
Free Cash Flow per Share	$-0.40
Operating Cash Flow per Share	$-0.40

Data from Zacks Investment Research, Inc.